Please assess the completion status of the following clinical trial:

Trial Title: Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed leiomyosarcoma (LMS) or other soft tissue sarcoma~  * No gastrointestinal stromal tumors, chondrosarcoma, Kaposi's sarcoma, Ewing's sarcoma, osteosarcoma, or mesotheliomas~* Recurrent or progressive disease defined as an increase in the size of any existing tumor (or the development of new tumors) that is not amenable to definitive surgical therapy~* No prior chemotherapy OR~* Failed no more than 2 prior chemotherapy regimens for LMS of the uterus or other soft tissue sarcoma~* Bidimensionally measurable disease by physical examination or medical imaging techniques~  * Ascites and pleural effusions are not considered measurable disease~* No uncontrolled CNS metastases~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count at least 1,500/mm\^3~* Platelet count at least 100,000/mm\^3~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~Renal:~* Creatinine no greater than 2.0 mg/dL~Other:~* No active or uncontrolled infection~* No other prior malignancy except non-metastatic squamous cell or basal cell skin cancer or non-invasive carcinoma in situ of the cervix~* No history of grade 3 or 4 peripheral neuropathy~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* See Disease Characteristics~* At least 3 weeks since prior chemotherapy~* No prior gemcitabine or docetaxel~Endocrine therapy:~* Not specified~Radiotherapy:~* At least 6 weeks since prior radiotherapy~Surgery:~* See Disease Characteristics

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).